472 related articles for article (PubMed ID: 32392801)
21. Metalloproteinases in melanoma.
Moro N; Mauch C; Zigrino P
Eur J Cell Biol; 2014; 93(1-2):23-9. PubMed ID: 24530009
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases: potential therapeutic target for diabetic neuropathic pain.
Kuhad A; Singh P; Chopra K
Expert Opin Ther Targets; 2015 Feb; 19(2):177-85. PubMed ID: 25243524
[TBL] [Abstract][Full Text] [Related]
23. The Roles of Matrix Metalloproteinases in Pancreatic Cancer.
Knapinska AM; Estrada CA; Fields GB
Prog Mol Biol Transl Sci; 2017; 148():339-354. PubMed ID: 28662827
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases and periodontal diseases.
Sapna G; Gokul S; Bagri-Manjrekar K
Oral Dis; 2014 Sep; 20(6):538-50. PubMed ID: 23849049
[TBL] [Abstract][Full Text] [Related]
25. Tamoxifen-induced alterations in the expression of selected matrix metalloproteinases (MMP-2, -9, -10, and -13) and their tissue inhibitors (TIMP-2 and -3) in the chicken ovary.
Wolak D; Hrabia A
Theriogenology; 2020 May; 148():208-215. PubMed ID: 31753476
[TBL] [Abstract][Full Text] [Related]
26. Beneficial regulation of matrixmetalloproteinases and their inhibitors, fibrillar collagens and transforming growth factor-beta by Polypodium leucotomos, directly or in dermal fibroblasts, ultraviolet radiated fibroblasts, and melanoma cells.
Philips N; Conte J; Chen YJ; Natrajan P; Taw M; Keller T; Givant J; Tuason M; Dulaj L; Leonardi D; Gonzalez S
Arch Dermatol Res; 2009 Aug; 301(7):487-95. PubMed ID: 19373483
[TBL] [Abstract][Full Text] [Related]
27. Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview.
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 May; 194():112260. PubMed ID: 32224379
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinase inhibition in atherosclerosis and stroke.
Roycik MD; Myers JS; Newcomer RG; Sang QX
Curr Mol Med; 2013 Sep; 13(8):1299-313. PubMed ID: 23865428
[TBL] [Abstract][Full Text] [Related]
29. Regulation of MMPs during melanoma progression: from genetic to epigenetic.
Frank A; David V; Aurelie TR; Florent G; William H; Philippe B
Anticancer Agents Med Chem; 2012 Sep; 12(7):773-82. PubMed ID: 22292748
[TBL] [Abstract][Full Text] [Related]
30. Matrix metaloproteinases in vascular pathology.
Simões G; Pereira T; Caseiro A
Microvasc Res; 2022 Sep; 143():104398. PubMed ID: 35671836
[TBL] [Abstract][Full Text] [Related]
31. Intricate Functions of Matrix Metalloproteinases in Physiological and Pathological Conditions.
Mittal R; Patel AP; Debs LH; Nguyen D; Patel K; Grati M; Mittal J; Yan D; Chapagain P; Liu XZ
J Cell Physiol; 2016 Dec; 231(12):2599-621. PubMed ID: 27187048
[TBL] [Abstract][Full Text] [Related]
32. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
33. Tension Force Downregulates Matrix Metalloproteinase Expression and Upregulates the Expression of Their Inhibitors through MAPK Signaling Pathways in MC3T3-E1 cells.
Karasawa Y; Tanaka H; Nakai K; Tanabe N; Kawato T; Maeno M; Shimizu N
Int J Med Sci; 2015; 12(11):905-13. PubMed ID: 26640410
[TBL] [Abstract][Full Text] [Related]
34. Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases.
Amar S; Minond D; Fields GB
Proteomics; 2017 Dec; 17(23-24):. PubMed ID: 28613012
[TBL] [Abstract][Full Text] [Related]
35. Perspectives and New Aspects of Metalloproteinases' Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine.
Boguszewska-Czubara A; Budzynska B; Skalicka-Wozniak K; Kurzepa J
Curr Med Chem; 2019; 26(18):3208-3224. PubMed ID: 29756562
[TBL] [Abstract][Full Text] [Related]
36. Matrix Metalloproteinases: A challenging paradigm of cancer management.
Alaseem A; Alhazzani K; Dondapati P; Alobid S; Bishayee A; Rathinavelu A
Semin Cancer Biol; 2019 Jun; 56():100-115. PubMed ID: 29155240
[TBL] [Abstract][Full Text] [Related]
37. Biochemical and Biological Attributes of Matrix Metalloproteinases.
Cui N; Hu M; Khalil RA
Prog Mol Biol Transl Sci; 2017; 147():1-73. PubMed ID: 28413025
[TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinases (MMPs): chemical-biological functions and (Q)SARs.
Verma RP; Hansch C
Bioorg Med Chem; 2007 Mar; 15(6):2223-68. PubMed ID: 17275314
[TBL] [Abstract][Full Text] [Related]
39. The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases.
de Bruyn M; Vandooren J; Ugarte-Berzal E; Arijs I; Vermeire S; Opdenakker G
Crit Rev Biochem Mol Biol; 2016 Sep; 51(5):295-358. PubMed ID: 27362691
[TBL] [Abstract][Full Text] [Related]
40. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in joint fluid of the patients with loose artificial hip joints.
Takei I; Takagi M; Santavirta S; Ida H; Hamasaki M; Ishii M; Fukushima S; Ogino T; Konttinen YT
J Biomed Mater Res; 1999 Jun; 45(3):175-83. PubMed ID: 10397973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
